DOCSLIB.ORG

Contents Volume 73 Issue 1 | ARD January 2014 Editorial Viewpoint

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Contents Volume 73 Issue 1 | ARD January 2014 Editorial Viewpoint Contents Volume 73 Issue 1 | ARD January 2014 The Eular Journal 56 Treatment of diffuse systemic sclerosis with Editorial hyperimmune caprine serum (AIMSPRO): a phase II 1 Classifi cation criteria for Sjogren’s syndrome: nothing OPEN ACCESS double-blind placebo-controlled trial ever stands still! N P Quillinan, D McIntosh, J Vernes, S Haq, C P Denton S J Bowman, R I Fox Ann Rheum Dis: first published as on 1 January 2014. Downloaded from 62 Prevalence of comorbidities in rheumatoid arthritis Viewpoint and evaluation of their monitoring: results of an OPEN ACCESS international, cross-sectional study (COMORA) 3 Proposal for a new nomenclature of disease-modifying M Dougados, M Soubrier, A Antunez, P Balint, A Balsa, antirheumatic drugs M H Buch, G Casado, J Detert, B El-zorkany, P Emery, J S Smolen, D van der Heijde, K P Machold, D Aletaha, N Hajjaj-Hassouni, M Harigai, S-F Luo, R Kurucz, G Maciel, R Landewé E M Mola, C M Montecucco, I McInnes, H Radner, J S Smolen, Y-W Song, H E Vonkeman, K Winthrop, J Kay Recommendations 69 A randomised, double-blind, parallel-group study of the 6 Treating spondyloarthritis, including ankylosing safety and effi cacy of subcutaneous tocilizumab versus Editor spondylitis and psoriatic arthritis, to target: OPEN ACCESS intravenous tocilizumab in combination with traditional Tore K Kvien OPEN ACCESS recommendations of an international task force disease-modifying antirheumatic drugs in patients with Associate Editors J S Smolen, J Braun, M Dougados, P Emery, O FitzGerald, moderate to severe rheumatoid arthritis (SUMMACTA Francis Berenbaum P Helliwell, A Kavanaugh, T K Kvien, R Landewé, T Luger, study) Hans Bijlsma P Mease, I Olivieri, J Reveille, C Ritchlin, M Rudwaleit, G R Burmester, A Rubbert-Roth, A Cantagrel, S Hall, David Pisetsky M Schoels, J Sieper, M de Wit, X Baraliakos, N Betteridge, P Leszczynski, D Feldman, M J Rangaraj, G Roane, Dimitrios Boumpas R Burgos-Vargas, E Collantes-Estevez, A Deodhar, D Elewaut, C Ludivico, P Lu, L Rowell, M Bao, E F Mysler Gerd Burmester L Gossec, M Jongkees, M Maccarone, K Redlich, Mary Crow F van den Bosch, J Cheng-Chung Wei, K Winthrop, Iain McInnes D van der Heijde 75 Remission induction comparing infl iximab and Editorial offi ce high-dose intravenous steroid, followed by treat-to- Annals of the Rheumatic Diseases 17 International recommendations for the assessment of target: a double-blind, randomised, controlled trial in BMJ Publishing Group Ltd autoantibodies to cellular antigens referred to as BMA House new-onset, treatment-naive, rheumatoid arthritis (the Tavistock Square anti-nuclear antibodies IDEA study) London WCIH 9JR,UK N Agmon-Levin, J Damoiseaux, C Kallenberg, U Sack, J L Nam, E Villeneuve, E M A Hensor, P G Conaghan, T: +44 (0)20 7383 6250 T Witte, M Herold, X Bossuyt, L Musset, R Cervera, H I Keen, M H Buch, A K Gough, M J Green, P S Helliwell, F: +44 (0)20 7383 6668 A Plaza-Lopez, C Dias, M José Sousa, A Radice, C Eriksson, A M Keenan, A W Morgan, M Quinn, R Reece, E: [email protected] O Hultgren, M Viander, M Khamashta, S Regenass, D M van der Heijde, R J Wakefi eld, P Emery ISSN: 0003-4967 (print) L E C Andrade, A Wiik, A Tincani, J Rönnelid, D B Bloch, ISSN: 1468-2060 (online) M J Fritzler, E K L Chan, I Garcia-De La Torre, Impact Factor: 9.111 K N Konstantinov, R Lahita, M Wilson, O Vainio, N Fabien, 86 Head-to-head comparison of subcutaneous abatacept R A Sinico, P Meroni, Y Shoenfeld versus adalimumab for rheumatoid arthritis: two-year http://ard.bmj.com/ Disclaimer: ARD is owned and published by OPEN ACCESS BMJ Publishing Group Ltd (a wholly owned effi cacy and safety fi ndings from AMPLE trial subsidiary of the British Medical Association) M Schiff, M E Weinblatt, R Valente, D van der Heijde, and the European League Against Rheumatism. The G Citera, A Elegbe, M Maldonado, R Fleischmann owners grant editorial freedom tothe Editor of ARD. Review ARD follows guidelines on editorial independence 24 Hepatitis C virus-induced vasculitis: therapeutic options produced by the World Association of Medical Editors P Cacoub, B Terrier, D Saadoun 95 Assessment of short-term symptomatic effi cacy and the code on good publication practice ofthe Committee on Publication Ethics. of tocilizumab in ankylosing spondylitis: results of ARD is intended for medical professionals and is OPEN ACCESS randomised, placebo-controlled trials on September 29, 2021 by guest. Protected copyright. provided without warranty, express or implied. Clinical and epidemiological research J Sieper, B Porter-Brown, L Thompson, O Harari, M Dougados Statements in the journal are the responsibility of their authors and advertisers and not authors’ 31 Comparison of the American-European Consensus institutions the BMJ Publishing Group, the European League Against Rheumatism or the Group Sjögren’s syndrome classifi cation criteria to BMA unless otherwise specifi ed or determined newly proposed American College of Rheumatology by law. Acceptance of advertising does not imply endorsement. criteria in a large, carefully characterised sicca cohort To the fullest extent permitted by law, the BMJ A Rasmussen, J A Ice, H Li, K Grundahl, J A Kelly, L Radfar, Publishing Group shall not be liable for any loss, injury D U Stone, K S Hefner, J-M Anaya, M Rohrer, or damage resulting from the use of ARD or any R Gopalakrishnan, G D Houston, D M Lewis, J Chodosh, information in it whether based on contract, tort, or J B Harley, P Hughes, J S Maier-Moore, C G Montgomery, otherwise. Readers are advised to verify any information they choose to rely on. N L Rhodus, A D Farris, B M Segal, R Jonsson, C J Lessard, R H Scofi eld, K L M Sivils Copyright: © 2014 BMJ Publishing Group and European League Against Rheumatism. All rights MORE CONTENTS ᭤ reserved; no part of this publication may be reproduced 39 Effi cacy of certolizumab pegol on signs and symptoms stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying of axial spondyloarthritis including ankylosing This article has been chosen by the Editor to be of special interest recording, or otherwise without prior permission OPEN ACCESS spondylitis: 24-week results of a double-blind or importance and is freely available online. ARD is published by BMJ Publishing Group Ltd typeset randomised placebo-controlled Phase 3 study by Techset and printed in the UK on acid-free paper. This article has been made freely available online under the BMJ R Landewé, J Braun, A Deodhar, M Dougados, Annals of the Rheumatic Diseases (ISSN No: Journals Open Access scheme. 0003-4967) is published monthly by BMJ Publishing W P Maksymowych, P J Mease, J D Reveille, M Rudwaleit, OPEN ACCESS Group and distributed in the USA by Air Business Ltd. D van der Heijde, C Stach, B Hoepken, A Fichtner, G Coteur, See http://ard.bmj.com/site/about/guidelines.xhtml#open Periodicals postage paid at Jamaica NY 11431 M de Longueville, J Sieper POSTMASTER: send address changes to Annals of the Rheumatic Diseases, Air Business Ltd, c/o Worldnet Shipping Inc., 156-15, 146th Avenue, 2nd Floor, 48 Effect of certolizumab pegol on signs and symptoms Jamaica, NY 11434, USA. in patients with psoriatic arthritis: 24-week results of This journal is a member of and subscribes to the principles of the OPEN ACCESS a Phase 3 double-blind randomised placebo-controlled Committee on Publication Ethics study (RAPID-PsA) www.publicationethics.org.uk P J Mease, R Fleischmann, A A Deodhar, J Wollenhaupt, M Khraishi, D Kielar, F Woltering, C Stach, B Hoepken, T Arledge, D van der Heijde Receive regular table of contents by email. Register using this QR code. Contents Volume 73 Issue 1 | ARD January 2014 101 Effi cacy and safety of infl iximab plus naproxen versus 177 Tophaceous gout and high level of hyperuricaemia naproxen alone in patients with early, active axial are both associated with increased risk of mortality in OPEN ACCESS spondyloarthritis: results from the double-blind, patients with gout placebo-controlled INFAST study, Part 1 F Perez-Ruiz, L Martínez-Indart, L Carmona, J Sieper, J Lenaerts, J Wollenhaupt, M Rudwaleit, V I Mazurov, A M Herrero-Beites, J I Pijoan, E Krishnan Ann Rheum Dis: first published as on 1 January 2014. Downloaded from L Myasoutova, S Park, Y Song, R Yao, D Chitkara, N Vastesaeger, on Behalf of All INFAST Investigators 183 Effi cacy and safety of epratuzumab in patients with moderate/severe active systemic lupus 108 Maintenance of biologic-free remission with naproxen OPEN ACCESS erythematosus: results from EMBLEM, a phase or no treatment in patients with early, active axial IIb, randomised, double-blind, placebo-controlled, OPEN ACCESS spondyloarthritis: results from a 6-month, randomised, multicentre study open-label follow-up study, INFAST Part 2 D J Wallace, K Kalunian, M A Petri, V Strand, J Sieper, J Lenaerts, J Wollenhaupt, M Rudwaleit, V I Mazurov, F A Houssiau, M Pike, B Kilgallen, S Bongardt, A Barry, L Myasoutova, S Park, Y Song, R Yao, D Chitkara, L Kelley, C Gordon N Vastesaeger, on Behalf of All INFAST Investigators 191 Expert consensus for performing right heart 114 Performance of the 2010 ACR/EULAR classifi cation catheterisation for suspected pulmonary arterial criteria for rheumatoid arthritis: a systematic literature hypertension in systemic sclerosis: a Delphi review consensus study with cluster analysis H Radner, T Neogi, J S Smolen, D Aletaha J Avouac, D Huscher, D E Furst, C F Opitz, O Distler, Y Allanore, for the EPOSS group 124 Open-label tofacitinib and double-blind atorvastatin in rheumatoid arthritis patients:
Load more

Recommended publications
  • Predictive QSAR Tools to Aid in Early Process Development of Monoclonal Antibodies
    Predictive QSAR tools to aid in early process development of monoclonal antibodies John Micael Andreas Karlberg Published work submitted to Newcastle University for the degree of Doctor of Philosophy in the School of Engineering November 2019 Abstract Monoclonal antibodies (mAbs) have become one of the fastest growing markets for diagnostic and therapeutic treatments over the last 30 years with a global sales revenue around $89 billion reported in 2017. A popular framework widely used in pharmaceutical industries for designing manufacturing processes for mAbs is Quality by Design (QbD) due to providing a structured and systematic approach in investigation and screening process parameters that might influence the product quality. However, due to the large number of product quality attributes (CQAs) and process parameters that exist in an mAb process platform, extensive investigation is needed to characterise their impact on the product quality which makes the process development costly and time consuming. There is thus an urgent need for methods and tools that can be used for early risk-based selection of critical product properties and process factors to reduce the number of potential factors that have to be investigated, thereby aiding in speeding up the process development and reduce costs. In this study, a framework for predictive model development based on Quantitative Structure- Activity Relationship (QSAR) modelling was developed to link structural features and properties of mAbs to Hydrophobic Interaction Chromatography (HIC) retention times and expressed mAb yield from HEK cells. Model development was based on a structured approach for incremental model refinement and evaluation that aided in increasing model performance until becoming acceptable in accordance to the OECD guidelines for QSAR models.
    [Show full text]
  • Challenges and Approaches for the Development of Safer Immunomodulatory Biologics
    REVIEWS Challenges and approaches for the development of safer immunomodulatory biologics Jean G. Sathish1*, Swaminathan Sethu1*, Marie-Christine Bielsky2, Lolke de Haan3, Neil S. French1, Karthik Govindappa1, James Green4, Christopher E. M. Griffiths5, Stephen Holgate6, David Jones2, Ian Kimber7, Jonathan Moggs8, Dean J. Naisbitt1, Munir Pirmohamed1, Gabriele Reichmann9, Jennifer Sims10, Meena Subramanyam11, Marque D. Todd12, Jan Willem Van Der Laan13, Richard J. Weaver14 and B. Kevin Park1 Abstract | Immunomodulatory biologics, which render their therapeutic effects by modulating or harnessing immune responses, have proven their therapeutic utility in several complex conditions including cancer and autoimmune diseases. However, unwanted adverse reactions — including serious infections, malignancy, cytokine release syndrome, anaphylaxis and hypersensitivity as well as immunogenicity — pose a challenge to the development of new (and safer) immunomodulatory biologics. In this article, we assess the safety issues associated with immunomodulatory biologics and discuss the current approaches for predicting and mitigating adverse reactions associated with their use. We also outline how these approaches can inform the development of safer immunomodulatory biologics. Immunomodulatory Biologics currently represent more than 30% of licensed The high specificity of the interactions of immu- biologics pharmaceutical products and have expanded the thera- nomodulatory biologics with their relevant immune Biotechnology-derived peutic options available
    [Show full text]
  • New Biological Therapies: Introduction to the Basis of the Risk of Infection
    New biological therapies: introduction to the basis of the risk of infection Mario FERNÁNDEZ RUIZ, MD, PhD Unit of Infectious Diseases Hospital Universitario “12 de Octubre”, Madrid ESCMIDInstituto de Investigación eLibraryHospital “12 de Octubre” (i+12) © by author Transparency Declaration Over the last 24 months I have received honoraria for talks on behalf of • Astellas Pharma • Gillead Sciences • Roche • Sanofi • Qiagen Infections and biologicals: a real concern? (two-hour symposium): New biological therapies: introduction to the ESCMIDbasis of the risk of infection eLibrary © by author Paul Ehrlich (1854-1915) • “side-chain” theory (1897) • receptor-ligand concept (1900) • “magic bullet” theory • foundation for specific chemotherapy (1906) • Nobel Prize in Physiology and Medicine (1908) (together with Metchnikoff) Infections and biologicals: a real concern? (two-hour symposium): New biological therapies: introduction to the ESCMIDbasis of the risk of infection eLibrary © by author 1981: B-1 antibody (tositumomab) anti-CD20 monoclonal antibody 1997: FDA approval of rituximab for the treatment of relapsed or refractory CD20-positive NHL 2001: FDA approval of imatinib for the treatment of chronic myelogenous leukemia Infections and biologicals: a real concern? (two-hour symposium): New biological therapies: introduction to the ESCMIDbasis of the risk of infection eLibrary © by author Functional classification of targeted (biological) agents • Agents targeting soluble immune effector molecules • Agents targeting cell surface receptors
    [Show full text]
  • Study Protocol
    PROTOCOL SYNOPSIS A Multicentre, Randomised, Double-blind, Placebo-controlled, Phase 3 Study Evaluating the Efficacy and Safety of Two Doses of Anifrolumab in Adult Subjects with Active Systemic Lupus Erythematosus International Coordinating Investigator Study site(s) and number of subjects planned Approximately 450 subjects are planned at approximately 173 sites. Study period Phase of development Estimated date of first subject enrolled Q2 2015 3 Estimated date of last subject completed Q2 2018 Study design This is a Phase 3, multicentre, multinational, randomised, double-blind, placebo-controlled study to evaluate the efficacy and safety of an intravenous treatment regimen of anifrolumab (150 mg or 300 mg) versus placebo in subjects with moderately to severely active, autoantibody-positive systemic lupus erythematosus (SLE) while receiving standard of care (SOC) treatment. The study will be performed in adult subjects aged 18 to 70 years of age. Approximately 450 subjects receiving SOC treatment will be randomised in a 1:2:2 ratio to receive a fixed intravenous dose of 150 mg anifrolumab, 300 mg anifrolumab, or placebo every 4 weeks (Q4W) for a total of 13 doses (Week 0 to Week 48), with the primary endpoint evaluated at the Week 52 visit. Investigational product will be administered as an intravenous (IV) infusion via an infusion pump over a minimum of 30 minutes, Q4W. Subjects must be taking either 1 or any combination of the following: oral corticosteroids (OCS), antimalarial, and/or immunosuppressants. Randomisation will be stratified using the following factors: SLE Disease Activity Index 2000 (SLEDAI-2K) score at screening (<10 points versus ≥10 points); Week 0 (Day 1) OCS dose 2(125) Revised Clinical Study Protocol Drug Substance Anifrolumab (MEDI-546) Study Code D3461C00005 Edition Number 5 Date 18 May 2016 (<10 mg/day versus ≥10 mg/day prednisone or equivalent); and results of a type 1 interferon (IFN) test (high versus low).
    [Show full text]
  • New Treatments for Systemic Lupus Erythematosus on the Horizon: Targeting Plasmacytoid Dendritic Cells to Inhibit Cytokine Production Laura M
    C al & ellu ic la n r li Im C m Journal of Clinical & Cellular f u o Davison and Jorgensen et al., J Clin Cell Immunol n l o a l n o 2017, 8:6 r g u y o J Immunology DOI: 10.4172/2155-9899.1000534 ISSN: 2155-9899 Commentary Open Access New Treatments for Systemic Lupus Erythematosus on the Horizon: Targeting Plasmacytoid Dendritic Cells to Inhibit Cytokine Production Laura M. Davison and Trine N. Jorgensen* Department of Immunology, Lerner Research Institute, Cleveland Clinic Foundation, Cleveland, Ohio, USA *Corresponding author: Dr. Trine N. Jorgensen, Department of Immunology, NE40, Lerner Research Institute, Cleveland Clinic Foundation, Ohio, USA, Phone: +1 216-444-7454; Fax: +1 216-444-9329; E-mail: [email protected] Received date: December 4, 2017; Accepted date: December 13, 2017; Published date: December 20, 2017 Copyright: © 2017 Davison LM, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Abstract Patients with systemic lupus erythematosus (SLE) often have elevated levels of type I interferon (IFN, particularly IFNα), a cytokine that can drive many of the symptoms associated with this autoimmune disorder. Additionally, the presence of autoantibody-secreting plasma cells contributes to the systemic inflammation observed in SLE and IFNα supports the survival of these cells. Current therapies for SLE are limited to broad immunosuppression or B cell- targeting antibody-mediated depletion strategies, which do not eliminate autoantibody-secreting plasma cells.
    [Show full text]
  • Advances in Interferon-Alpha Targeting-Approaches for Systemic Lupus Erythematosus Treatment
    Full title: Advances in Interferon-alpha targeting-approaches for Systemic Lupus Erythematosus treatment Running title: Interferon-alpha targeting in SLE Authors: Filipa Farinha - Rheumatology Department, Centro Hospitalar do Baixo Vouga E.P.E. – Aveiro, Portugal David A Isenberg - Centre for Rheumatology, Division of Medicine, University College London – London, UK Correspondence to: Professor David Isenberg The Rayne Building Room 424, 4th Floor 5 University Street London WC1E 6JF E-mail: [email protected] Tel: 0044 203 108 2148 Fax: 0044 203 108 2152 1 Contents Summary 1. Introduction 1.1. IFN alpha 1.2. IFN alpha and SLE 2. IFN alpha targeting approaches 2.1. Anti-IFN alpha antibodies 2.2. Anti-IFN alpha receptor antibodies 2.3. IFN alpha Kinoid 3. Discussion 4. Conclusion Acknowledgements References 2 Summary Conventional therapies seem to have reached the limit of their ability to treat patients with Systemic Lupus Erythematosus (SLE). To improve the outcome for these patients, new drugs are needed. Several attempts have been made to introduce targeted therapies for this complex disease. One of these targets is Interferon (IFN) alpha, whose production is increased in SLE, contributing to its pathogenesis. In this review we consider some recent advances in IFN alpha targeting-approaches. Three monoclonal antibodies (mAbs) against several IFN alpha subtypes have been tested in phase I and II trials, showing an acceptable safety profile and promising results in terms of reducing the IFN signature and disease activity. A mAb specific for the IFN alpha receptor and active immunization against IFN alpha are also being tested. Further trials will be essential to ascertain the safety and efficacy of all these approaches.
    [Show full text]
  • New Drug Therapies for Systemic Lupus
    icine- O ed pe M n l A a c n c r e e s t s n I Beenken, Intern Med 2018, 8:1 Internal Medicine: Open Access DOI: 10.4172/2165-8048.1000268 ISSN: 2165-8048 Review Article Open Access New Drug Therapies for Systemic Lupus Erythematosus: A Systematic Review Beenken AE* Institute for Medical Immunology at the Campus Charité Mitte of the Medical Faculty of the Charité - Universitätsmedizin Berlin, Germany *Corresponding author: Beenken AE, Institute for Medical Immunology, Berlin, Germany, Tel: 4915161419493; E-mail: [email protected] Received date: January 31, 2018; Accepted date: February 20, 2018; Published date: February 25, 2018 Copyright: © 2018 Beenken AE, This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited Abstract From the literature research the belimumab studies were the only ones to meet the primary and some of the secondary endpoints. Introduction: Systemic Lupus Erythematosus (SLE) is a multiorganic autoimmune disease caused by an immune reaction against DNA. Despite continuous research progress, the mortality of SLE patients is still 2‐4 times higher than the healthy populations and the standard drugs’ adverse effects (especially corticosteroids) hamper the patients’ quality of life. That is why there is an urgent need for new therapies. This paper reviews all phase III clinical trials of new SLE medication that were published since 2011 and analyses the drugs for their respective effects. Methods: MEDLINE (PubMed), Livivo, The Cochrane Library and Embase were systematically searched for relevant publications.
    [Show full text]
  • Efficacy and Safety of Epratuzumab in Patients With
    Efficacy and safety of epratuzumab in patients with moderate/severe active systemic lupus erythematosus: results from EMBLEM, a phase IIb, randomised, double-blind, placebo- controlled, multicentre study The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters Citation Wallace, D. J., K. Kalunian, M. A. Petri, V. Strand, F. A. Houssiau, M. Pike, B. Kilgallen, et al. 2014. “Efficacy and safety of epratuzumab in patients with moderate/severe active systemic lupus erythematosus: results from EMBLEM, a phase IIb, randomised, double-blind, placebo-controlled, multicentre study.” Annals of the Rheumatic Diseases 73 (1): 183-190. doi:10.1136/annrheumdis-2012-202760. http://dx.doi.org/10.1136/ annrheumdis-2012-202760. Published Version doi:10.1136/annrheumdis-2012-202760 Citable link http://nrs.harvard.edu/urn-3:HUL.InstRepos:11879596 Terms of Use This article was downloaded from Harvard University’s DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at http:// nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of- use#LAA Clinical and epidemiological research EXTENDED REPORT Efficacy and safety of epratuzumab in patients with moderate/severe active systemic lupus erythematosus: results from EMBLEM, a phase IIb, randomised, double-blind, placebo-controlled, multicentre study Daniel J Wallace,1 Kenneth Kalunian,2 Michelle A Petri,3 Vibeke Strand,4 Frederic A Houssiau,5 Marilyn Pike,6 Brian Kilgallen,7 Sabine Bongardt,8 Anna Barry,7 Lexy Kelley,7 Caroline Gordon9,10 Handling editor Tore K Kvien ABSTRACT underlying pathogenesis of SLE is increasing and a ▸ Additional material is Objective To identify a suitable dosing regimen of the number of promising therapeutic targets have been published online only.
    [Show full text]
  • Tables-Of-Phase-3-Mabs.Pdf
    Table 3. Monoclonal antibodies in Phase 2/3 or 3 clinical studies for cancer indications Most advanced Primary sponsoring company INN or code name Molecular format Target(s) phase Phase 3 indications Therapeutic area Janssen Research & Development, LLC JNJ-56022473 Humanized mAb CD123 Phase 2/3 Acute myeloid leukemia Cancer Murine IgG1, Actinium Pharmaceuticals Iomab-B radiolabeled CD45 Phase 3 Acute myeloid leukemia Cancer Humanized IgG1, Seattle Genetics Vadastuximab talirine ADC CD33 Phase 3 Acute myeloid leukemia Cancer TG Therapeutics Ublituximab Chimeric IgG1 CD20 Phase 3 Chronic lymphocytic leukemia Cancer Xencor XMAB-5574, MOR208 Humanized IgG1 CD19 Phase 2/3 Diffuse large B-cell lymphoma Cancer Moxetumomab Murine IgG1 dsFv, AstraZeneca/MedImmune LLC pasudotox immunotoxin CD22 Phase 3 Hairy cell leukemia Cancer Humanized scFv, Viventia Bio Oportuzumab monatox immunotoxin EpCAM Phase 3 Bladder cancer Cancer scFv-targeted liposome containing Merrimack Pharmaceuticals MM-302 doxorubicin HER2 Phase 2/3 Breast cancer Cancer MacroGenics Margetuximab Chimeric IgG1 HER2 Phase 3 Breast cancer Cancer Gastric cancer or gastroesophageal junction Gilead Sciences GS-5745 Humanized IgG4 MMP9 Phase 3 adenocarcinoma; ulcerative colitis (Phase 2/3) Cancer; Immune-mediated disorders Depatuxizumab Humanized IgG1, AbbVie mafodotin ADC EGFR Phase 2/3 Glioblastoma Cancer AstraZeneca/MedImmune LLC Tremelimumab Human IgG2 CTLA4 Phase 3 NSCLC, head & neck cancer, bladder cancer Cancer NSCLC, head & neck cancer, bladder cancer, breast AstraZeneca/MedImmune
    [Show full text]
  • The Two Tontti Tudiul Lui Hi Ha Unit
    THETWO TONTTI USTUDIUL 20170267753A1 LUI HI HA UNIT ( 19) United States (12 ) Patent Application Publication (10 ) Pub. No. : US 2017 /0267753 A1 Ehrenpreis (43 ) Pub . Date : Sep . 21 , 2017 ( 54 ) COMBINATION THERAPY FOR (52 ) U .S . CI. CO - ADMINISTRATION OF MONOCLONAL CPC .. .. CO7K 16 / 241 ( 2013 .01 ) ; A61K 39 / 3955 ANTIBODIES ( 2013 .01 ) ; A61K 31 /4706 ( 2013 .01 ) ; A61K 31 / 165 ( 2013 .01 ) ; CO7K 2317 /21 (2013 . 01 ) ; (71 ) Applicant: Eli D Ehrenpreis , Skokie , IL (US ) CO7K 2317/ 24 ( 2013. 01 ) ; A61K 2039/ 505 ( 2013 .01 ) (72 ) Inventor : Eli D Ehrenpreis, Skokie , IL (US ) (57 ) ABSTRACT Disclosed are methods for enhancing the efficacy of mono (21 ) Appl. No. : 15 /605 ,212 clonal antibody therapy , which entails co - administering a therapeutic monoclonal antibody , or a functional fragment (22 ) Filed : May 25 , 2017 thereof, and an effective amount of colchicine or hydroxy chloroquine , or a combination thereof, to a patient in need Related U . S . Application Data thereof . Also disclosed are methods of prolonging or increasing the time a monoclonal antibody remains in the (63 ) Continuation - in - part of application No . 14 / 947 , 193 , circulation of a patient, which entails co - administering a filed on Nov. 20 , 2015 . therapeutic monoclonal antibody , or a functional fragment ( 60 ) Provisional application No . 62/ 082, 682 , filed on Nov . of the monoclonal antibody , and an effective amount of 21 , 2014 . colchicine or hydroxychloroquine , or a combination thereof, to a patient in need thereof, wherein the time themonoclonal antibody remains in the circulation ( e . g . , blood serum ) of the Publication Classification patient is increased relative to the same regimen of admin (51 ) Int .
    [Show full text]
  • (LLDAS) Attainment Discriminates Responders in a Systemic Lupus
    ARD Online First, published on February 2, 2018 as 10.1136/annrheumdis-2017-212504 Ann Rheum Dis: first published as 10.1136/annrheumdis-2017-212504 on 2 February 2018. Downloaded from Clinical and epidemiological research EXTENDED REPORT Lupus Low Disease Activity State (LLDAS) attainment discriminates responders in a systemic lupus erythematosus trial: post-hoc analysis of the Phase IIb MUSE trial of anifrolumab Eric F Morand,1 Teodora Trasieva,2 Anna Berglind,2 Gabor G Illei,3 Raj Tummala4 Handling editor Josef S ABSTRacT identified as a key research goal.3 4 In response to Smolen Objectives In a post-hoc analysis, we aimed to validate this unmet need, increasing evidence suggests that the Lupus Low Disease Activity State (LLDAS) definition the Lupus Low Disease Activity State (LLDAS) ► Additional material is published online only. To view as an endpoint in an systemic lupus erythematosus represents a clinically meaningful state with poten- please visit the journal online (SLE) Phase IIb randomised controlled trial (RCT) (MUSE tial utility in both research and clinical settings.5 (http:// dx. doi. org/ 10. 1136/ [NCT01438489]) and then utilize LLDAS to discriminate Patients with SLE who spend the majority of their annrheumdis- 2017- 212504). between anifrolumab and placebo. time in LLDAS are protected from damage accrual, 1Centre for Inflammatory Methods Patients received intravenous placebo and LLDAS is also associated with better health-re- Diseases, Monash University, (n=102) or anifrolumab (300 mg, n=99; 1,000 mg, lated quality of life (HRQOL) and is more stringent Melbourne, Victoria, Australia n=104) Q4W plus standard of care for 48 weeks.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2017/0172932 A1 Peyman (43) Pub
    US 20170172932A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2017/0172932 A1 Peyman (43) Pub. Date: Jun. 22, 2017 (54) EARLY CANCER DETECTION AND A 6LX 39/395 (2006.01) ENHANCED IMMUNOTHERAPY A61R 4I/00 (2006.01) (52) U.S. Cl. (71) Applicant: Gholam A. Peyman, Sun City, AZ CPC .......... A61K 9/50 (2013.01); A61K 39/39558 (US) (2013.01); A61K 4I/0052 (2013.01); A61 K 48/00 (2013.01); A61K 35/17 (2013.01); A61 K (72) Inventor: sham A. Peyman, Sun City, AZ 35/15 (2013.01); A61K 2035/124 (2013.01) (21) Appl. No.: 15/143,981 (57) ABSTRACT (22) Filed: May 2, 2016 A method of therapy for a tumor or other pathology by administering a combination of thermotherapy and immu Related U.S. Application Data notherapy optionally combined with gene delivery. The combination therapy beneficially treats the tumor and pre (63) Continuation-in-part of application No. 14/976,321, vents tumor recurrence, either locally or at a different site, by filed on Dec. 21, 2015. boosting the patient’s immune response both at the time or original therapy and/or for later therapy. With respect to Publication Classification gene delivery, the inventive method may be used in cancer (51) Int. Cl. therapy, but is not limited to such use; it will be appreciated A 6LX 9/50 (2006.01) that the inventive method may be used for gene delivery in A6 IK 35/5 (2006.01) general. The controlled and precise application of thermal A6 IK 4.8/00 (2006.01) energy enhances gene transfer to any cell, whether the cell A 6LX 35/7 (2006.01) is a neoplastic cell, a pre-neoplastic cell, or a normal cell.
    [Show full text]